NEWBORN SCREENING STUDY
Newborn Bloodspot Screening of infants is an effective public health measure in Australia, that primarily involves biochemical testing for approximately 25 conditions.
Our Newborn Screening study aims to incorporate Targeted, Adaptive Genomic Newborn Bloodspot Screening (TAG-NBS) into the existing model of newborn screening, with the hopes of expanding the amount of treatable conditions that can be screened for to 132 conditions. One of the objectives to achieve this involves reforming the consent pathway for newborn screening, and confirming conditions to be added to the newborn screening program. Alongside this, we will investigate the psychosocial impact of TAG-NBS through exploring the Australian public’s attitudes towards expanded screening.
Participants include parents of infants < 12 months old as well as the general public, Australia-wide.
Our Newborn Screening study aims to incorporate Targeted, Adaptive Genomic Newborn Bloodspot Screening (TAG-NBS) into the existing model of newborn screening, with the hopes of expanding the amount of treatable conditions that can be screened for to 132 conditions. One of the objectives to achieve this involves reforming the consent pathway for newborn screening, and confirming conditions to be added to the newborn screening program. Alongside this, we will investigate the psychosocial impact of TAG-NBS through exploring the Australian public’s attitudes towards expanded screening.
Participants include parents of infants < 12 months old as well as the general public, Australia-wide.